March 28, 2023 by Chain Drug Review
second quarter, WBA, WBA's second quarter results beat expectations
Business, Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance’s second quarter sales and earnings topped Wall Street’s forecast, even as its net profit slid more than 20%. The company reported adjusted earnings per share of $1.16 on revenue of $34.9 billion (up 3.3%). Analysts had estimated adjusted EPS of $1.10 on revenue of $33.5 billion. WBA’s net profit
January 5, 2023 by Chain Drug Review
first quarter, WBA
Featured Articles, Leading Headlines

DEERFIELD, Ill. — Walgreens Boots Alliance posted first quarter sales and earnings that topped analysts’ forecasts. WBA reported adjusted earnings per share of $1.16, surpassing the expected $1.14. Revenue for the three-month period ended Nov. 30 was $33.38 billion, ahead of the projected $32.84 billion. Walgreens’ front end sales grew 0.8 percent, with same-store sales
November 10, 2022 by Chain Drug Review
Holly May, The goal is a core component of the company’s expanded U.S. health equity performance goal, WBA
Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance, Inc. (WBA) has announced it is strengthening its commitment to increasing the representation of people with disabilities at all levels across the company’s U.S. segments and redesigning its annual bonus plan in the U.S. to include a disability representation metric to drive this commitment. The company will be the
November 8, 2022 by Chain Drug Review
Amerisource Bergen, WBA
Business, Leading Headlines

DEERFIELD, Ill. – Walgreens Boots Alliance, Inc. (WBA) announced Monday that it has commenced an offering of 10 million shares of AmerisourceBergen Corp. common stock in a registered public offering and, subject to the completion of the offering, a concurrent share repurchase by AmerisourceBergen in the amount of approximately $500 million. After the sale, Walgreens
October 13, 2022 by Chain Drug Review
Brewer, fourth quarter, WBA
Featured Articles, Leading Headlines

DEERFIELD, Ill. _ Walgreens Boots Alliance topped analysts’ projections for fourth quarter revenue and earnings. WBA posted adjusted earnings per share of 80 cents for the period ended Aug. 31, exceeding Wall Street’s expectation of 77 cents. Revenue of $32.45 billion surpassed the predicted $32.09 billion. A fall off in COVID-19 vaccinations and a charge
October 11, 2022 by Chain Drug Review
CareCentrix, Driscoll, WBA
Featured Articles, Leading Headlines, Uncategorized

DEERFIELD, Ill. — Walgreens Boots Alliance Inc., which acquired a majority stake in CareCentrix in August, is moving ahead to take full ownership of the home care company. WBA says the move will expand its reach into the growing home care sector and advance its long-term healthcare growth strategy. CareCentrix CEO John Driscoll will assume
September 20, 2022 by Chain Drug Review
John Standley, Lee Cooper, Roz Brewer, WBA
Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. – Walgreens Boots Alliance (WBA) announced on Tuesday a new leadership structure for its U.S. business segment with Walgreens president John Standley leaving the company to pursue other opportunities. The new segment will now be organized under two leaders: Pharmacy led by Lee Cooper, and Retail led by Tracey Brown, president, Walgreens Retail
September 8, 2022 by Chain Drug Review
Hsiao Wang, Inderpal Bhandar, WBA
Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) announced Thursday that it is further strengthening its leadership with the appointments of Inderpal Bhandari to its board of directors and Hsiao Wang as senior vice president and chief information officer (CIO), bringing deep technology expertise in the healthcare and retail sectors. The company’s board of directors has
August 31, 2022 by Chain Drug Review
CareCentrix, WBA
Featured Articles, Leading Headlines, Pharmacy, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) announced Wednesday it has completed its previously announced majority share acquisition of CareCentrix, Inc.—the leading independent home-centered platform that coordinates care to the home for health plans, patients and providers. The majority investment in CareCentrix accelerates Walgreens Health’s capabilities in delivering quality healthcare across a spectrum of settings
August 30, 2022 by Chain Drug Review
Alethia Jackson, WBA
Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) announced Tuesday that Alethia Jackson has been named senior vice president, ESG (environmental, social and governance) and chief DEI (diversity, equity and inclusion) officer for the U.S. Jackson most recently served as vice president, federal government relations for Walgreens, and will assume her new role Oct. 1. She
August 17, 2022 by Chain Drug Review
Roz Brewer, WBA
Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) announced Wednesday that it has sold 11.0 million shares of Option Care Health common stock in an underwritten secondary offering. After the sale, Walgreens Boots Alliance’s ownership of Option Care Health’s common stock has decreased from approximately 20.5% to approximately 14.4%. Walgreens Boots Alliance intends to use the
June 30, 2022 by Chain Drug Review
AllianceRx Walgreens, Brewer, third quarter, WBA
Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance posted third quarter sales and earnings that beat Wall Street’s projections. The company’s adjusted earnings per share of 96 cents topped analysts’ forecast of 92 cents, while its revenue of $32.6 billion exceeded the predicted $32.06 billion. WBA said it was maintaining its full year adjusted EPS guidance of
June 28, 2022 by Chain Drug Review
Boots, No7 Beauty Company, Rosalind Brewer, WBA
Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) announced on Tuesday its decision to keep its Boots and No7 Beauty Company businesses under its existing ownership. This marks the conclusion of the review that began in January in line with the company’s strategic priorities. WBA has been encouraged by productive discussions held with a range of
May 11, 2022 by Chain Drug Review
AmerisourceBergen, WBA
Business, Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill.– Walgreens Boots Alliance, Inc. (WBA) has sold 6.0 million shares of AmerisourceBergen Corp. common stock pursuant to Rule 144 at a price of $150 per share. After the sale, Walgreens Boots Alliance’s ownership of AmerisourceBergen’s common stock has decreased from approximately 28.1% to approximately 25.2%. The sale has no impact to the long-term